Artivion (NYSE:AORT) SVP Jean Holloway Sells 977 Shares

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 977 shares of the business’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $28.49, for a total transaction of $27,834.73. Following the completion of the sale, the senior vice president directly owned 184,118 shares in the company, valued at approximately $5,245,521.82. This represents a 0.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Artivion Stock Up 1.3%

Artivion stock opened at $28.77 on Thursday. The company has a market cap of $1.40 billion, a P/E ratio of -410.94 and a beta of 1.25. Artivion, Inc. has a 1-year low of $19.16 and a 1-year high of $48.25. The company has a fifty day simple moving average of $23.95 and a 200 day simple moving average of $30.71. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82.

Artivion (NYSE:AORT) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.13 earnings per share (EPS) for the quarter. The firm had revenue of $125.76 million for the quarter, compared to analyst estimates of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. Research analysts anticipate that Artivion, Inc. will post 0.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd acquired a new stake in Artivion during the third quarter worth approximately $27,000. Rockefeller Capital Management L.P. increased its stake in shares of Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after purchasing an additional 399 shares during the period. Larson Financial Group LLC lifted its holdings in Artivion by 148.5% during the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares during the last quarter. KBC Group NV bought a new stake in Artivion in the 4th quarter valued at $65,000. Finally, First Horizon Corp boosted its stake in Artivion by 199.4% in the 4th quarter. First Horizon Corp now owns 1,602 shares of the company’s stock valued at $73,000 after purchasing an additional 1,067 shares during the period. Institutional investors and hedge funds own 86.37% of the company’s stock.

Analyst Ratings Changes

AORT has been the subject of a number of analyst reports. Stifel Nicolaus set a $45.00 price target on Artivion in a research note on Monday, June 1st. Citigroup reissued a “market outperform” rating on shares of Artivion in a report on Tuesday, July 21st. Weiss Ratings cut shares of Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday. Wall Street Zen downgraded shares of Artivion from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $44.00 price target on shares of Artivion in a research report on Monday, July 20th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Artivion presently has an average rating of “Moderate Buy” and a consensus price target of $44.67.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.